Autologous SVF Injection
Pain and dysfunction from moderate-to-severe osteoarthritis of the knee
Key Facts
About GID Bio
GID Bio is a late-stage private biotech company advancing an autologous Stromal Vascular Fraction (SVF) cell therapy for moderate-to-severe knee osteoarthritis. The company has successfully completed a pivotal Phase 3 FDA IDE clinical trial, demonstrating statistically significant pain reduction and functional improvement versus sham control, with no reported adverse safety events. GID Bio is now preparing a Premarket Approval (PMA) submission to the FDA, positioning it as a potential non-surgical, cell-based therapeutic option for a large and underserved patient population. The leadership team combines deep expertise in regenerative medicine science, medical device development, and commercial healthcare operations.
View full company profile